EdgeScore

MBRX · Nasdaq

Moleculin Biotech, Inc.: financial statements

Insufficient data · see the checkFigures in USD, fiscal years

Revenue and net income

Revenue 2020: $0Net income 2020: -$17.4M2020Revenue 2021: $0Net income 2021: -$15.9M2021Revenue 2022: $0Net income 2022: -$29.0M2022Revenue 2023: $0Net income 2023: -$29.8M2023Revenue 2024: $0Net income 2024: -$26.0M2024Revenue 2025: $0Net income 2025: -$33.6M2025
RevenueNet income

Operating and free cash flow

Operating cash flow 2020: -$17.8MFree cash flow 2020: -$18.1M2020Operating cash flow 2021: -$19.0MFree cash flow 2021: -$19.0M2021Operating cash flow 2022: -$27.6MFree cash flow 2022: -$27.7M2022Operating cash flow 2023: -$23.6MFree cash flow 2023: -$23.7M2023Operating cash flow 2024: -$23.9MFree cash flow 2024: -$23.9M2024Operating cash flow 2025: -$22.7MFree cash flow 2025: -$22.7M2025
Operating cash flowFree cash flow

Returns

ROE 2020: -97.7%ROE 2021: -20.1%ROE 2022: -55.6%ROE 2023: -96.3%ROE 2024: -232.4%ROE 2025: -223.6%ROIC 2020: -763.1%ROIC 2021: -339.9%ROIC 2022: -282.5%ROIC 2023: -285.1%ROIC 2024: -372.4%ROIC 2025: -384.5%ROA 2020: -59.8%ROA 2021: -18.9%ROA 2022: -50.5%ROA 2023: -77.9%ROA 2024: -153.9%ROA 2025: -151.7%202020212022202320242025
ROEROICROA

Income statement

USD202020212022202320242025Last year
Revenue$0$0$0$0$0$0
Operating income-$19.7M-$23.0M-$30.6M-$29.6M-$26.6M-$25.1M+6%
EBITDA-$19.5M-$22.8M-$30.5M-$29.5M-$26.5M-$25.0M+6%
Interest expense$0$0————
Profit before tax-$17.4M———-$26.0M-$33.6M-29%
Income tax$0$0$0$0$0$0
Net income-$17.4M-$15.9M-$29.0M-$29.8M-$26.0M-$33.6M-29%

Cash flow

USD202020212022202320242025Last year
Operating cash flow-$17.8M-$19.0M-$27.6M-$23.6M-$23.9M-$22.7M+5%
Capital expenditure$376K$19.0K$67.0K$124K$13.0K$0-100%
Free cash flow-$18.1M-$19.0M-$27.7M-$23.7M-$23.9M-$22.7M+5%
Depreciation & amortization$200K$164K$130K$127K$126K$90.0K-29%

Balance sheet

USD202020212022202320242025Last year
Cash$15.2M$70.9M$43.1M$23.6M$4.3M$8.9M+108%
Current assets$17.2M$72.5M$45.6M$26.3M$5.2M$9.7M+86%
Total assets$29.0M$84.1M$57.4M$38.2M$16.9M$22.1M+31%
Current liabilities$2.9M$3.6M$4.8M$6.8M$5.4M$6.9M+28%
Total liabilities$11.3M$5.1M$5.2M$12.1M$5.7M$7.1M+25%
Shareholders' equity$17.8M$79.0M$52.2M$30.9M$11.2M$15.0M+34%
Net debt-$15.2M-$70.9M-$43.1M-$23.6M-$4.3M-$8.9M-108%

Ratios

202020212022202320242025Last year
Return on equity-97.7%-20.1%-55.6%-96.3%-232.4%-223.6%
Return on assets-59.8%-18.9%-50.5%-77.9%-153.9%-151.7%
Return on invested capital-763.1%-339.9%-282.5%-285.1%-372.4%-384.5%
Current ratio5.8920.029.463.860.971.41
Quick ratio5.8920.029.463.860.971.41

Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.

For information and education only. Not investment advice. Data may contain errors.